|Bid||152.33 x 200|
|Ask||152.40 x 100|
|Day's Range||150.17 - 153.48|
|52 Week Range||134.25 - 178.86|
|PE Ratio (TTM)||6.70|
|Earnings Date||May 16, 2018 - May 21, 2018|
|Forward Dividend & Yield||1.36 (0.90%)|
|1y Target Est||178.88|
As part of its revamped focus, the drug distributor agreed to buy Medical Specialties Distributors from New Mountain Capital.
McKesson Corporation (MCK) today announced a multi-year strategic growth initiative, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure, designed to increase efficiency, accelerate execution and improve long-term performance. McKesson expects investments in these areas will accelerate the company’s growth trajectory over the long term.
Glenview Capital Management Chief Executive Larry Robbins said on Monday at the Sohn Investment Conference in New York that he still likes a trio of stocks he already owns, citing CVS Health Corp (CVS.N), McKesson Corp (MCK.N) and Express Scripts Holdings (ESRX.O). Amazon has not made significant hires in the pharmacy business and does not have the licenses needed to enter the business, Robbins said. Amazon's entry into the business of selling medications, is "neither imminent, assured, nor likely to succeed," he said.
Glenview Capital Management Chief Executive Larry Robbins said on Monday at the Sohn Investment Conference in New York that he still likes a trio of stocks he already owns, citing CVS Health Corp, McKesson Corp and Express Scripts Holdings. Amazon has not made significant hires in the pharmacy business and does not have the licenses needed to enter the business, Robbins said. Amazon's entry into the business of selling medications, is "neither imminent, assured, nor likely to succeed," he said.
A year after McKesson Corp. announced a $150 million settlement with the U.S. government over allegations it failed to properly oversee shipments of painkillers, a board committee cleared directors and ...
Shares of Cardinal Health, McKesson, AmerisourceBergen, Walgreens Boots Alliance and CVS Health all rose on the news.
A House committee trying to understand how the opioid crisis came to be and what to do next has set a May 8 hearing for drug distributors to explain their role.
Examining McKesson Corporation’s (NYSE:MCK) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...
COLUMBUS, Ohio (AP) — A federal judge with an audacious plan to settle hundreds of lawsuits filed by local governments against the drug industry over the destruction wrought by prescription opioid painkillers has altered his course.
Adynxx's first goal is to have its experimental drug block post-surgical pain, but in doing that it appears to have an effect on how many addictive opioids patients will pop.
McKesson and other drug distributors are having a difficult time steering clear of controversy, with the latest blow a lawsuit alleging McKesson has violated the False Claims Act.
Netsmart will acquire the home health and hospice businesses from one of the world's largest health care companies.
The co-working company, valued at $20 billion, shows no signs of slowing after a blockbuster year in 2017.
Opioids were responsible for 115 deaths of Americans per day in 2016. Now the San Francisco-based company responsible for distributing many of those painkillers is proposing ways to fight the opioid crisis.
Stocks, such as McKesson, trading at a market price below their true values are considered to be undervalued. There’s a few ways you can measure the value of a companyRead More...
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MCK. Over the last one-month, outflows of investor capital in ETFs holding MCK totaled $2.54 billion.
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
After months of inaction by the federal government on the crisis regarding opioid abuse, Attorney General Jeff Sessions announced the creation of a task force charged with looking at how drug makers and ...